Thursday, October 24, 2013
This week in
Publication and contact
Programmed cell death 1 (PDCD1;
PD-1; CD279); programmed cell death 1 ligand 1
(CD274 molecule; PD-L1; B7-H1); epidermal growth factor receptor
Primary tumor and mouse
studies suggest inhibitors of PD-1 and PD-L1 could help treat lung cancer
harboring EGFR mutations. In primary lung tumors and transgenic mouse
models of lung cancer, mutations in EGFR were associated with
increased expression of PD-1 or PD-L1. In transgenic mouse models with EGFR
mutations, a murine anti-Pd-1 mAb decreased tumor growth and increased
survival compared with no treatment. Ongoing work includes testing
combinations of EGFR and PD-1 or
PD-L1 inhibitors in mouse models of lung cancer.
Pharmaceutical Co. Ltd. and Bristol-Myers
Squibb Co. have nivolumab
(ONO-4538; MDX-1106; BMS-936558), a human mAb
against PD-1, in Phase III testing to treat non-small cell lung cancer
(NSCLC), renal cancer and melanoma and in Phase I testing to treat liver
cancer and solid tumors.
and its Genentech
Inc. unit have RG7446 (MPDL3280A), a human mAb
against PD-L1, in Phase II
testing to treat NSCLC and Phase I testing to treat melanoma and solid
Merck & Co. Inc. has MK-3475, an anti-PD-1 mAb,
in Phase II/III trials to treat NSCLC and in Phase III testing to treat
At least five other companies have anti-PD-1 or anti-PD-L1 antibodies in
Phase II or earlier development.
Published online Oct. 24, 2013
available for partnering
Akbay, E.A. et al.
Cancer Discov.; published online Sept. 27, 2013;
Contact: Kwok-Kin Wong, Dana-Farber Cancer Institute,
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]